Hence, this study aimed to investigate the prevalence of OBR, the details of bone metastasis and OBR, and the association between OBR and clinical outcomes in patients with EGFR-mutant advanced NSCLC treated with osimertinib. This evidence concerns the gene EGFR and bone metastasis.